Pharmacogenetic testing among patients with depression in a US managed care population
Abstract Actionable drug-gene pairs relevant to depression treatment include CYP2D6 and CYP2C19 with specific antidepressants. While clinical use of pharmacogenetic testing is growing, little is known about pharmacogenetic testing for depression treatment in managed care. We determined the incidence...
Saved in:
Main Authors: | Heather D. Anderson (Author), Thida M. Thant (Author), David P. Kao (Author), Kristy R. Crooks (Author), Nicholas D. Mendola (Author), Christina L. Aquilante (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mental Health Prescribers’ Perceptions on the Use of Pharmacogenetic Testing in the Management of Depression in the Middle East and North Africa Region
by: Aboelbaha S, et al.
Published: (2023) -
Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings
by: D. Max Smith, et al.
Published: (2020) -
Pharmacogenetic implications in the management of metabolic diseases in Brazilian populations
by: Rosario Dominguez Crespo Hirata, et al.
Published: (2018) -
Pharmacogenetics in the Brazilian population
by: Guilherme eSuarez-Kurtz
Published: (2010) -
Pharmacogenetic testing in primary care could bolster depression treatment: A value proposition
by: Nina R. Sperber, et al.
Published: (2024)